InSphero at Drug Discovery 2025
Don't miss us at Drug Discovery 2025 in Liverpool! This leading conference in drug discovery and innovation will explore new approaches that are decreasing reliance on animal models and icreasing advances in sustainable drug research.
Join us as we share new insights about 3D in vitro models and how they are driving therapeutic innovation! Drug Discovery 2025 is taking place from Tuesday, October 21st to Wednesday, October 22nd.
Quick navigation
Meet our Team at Drug Discovery 2025


Madhu Nag, PhD
Chief Scientific Officer
Madhu Nag, PhD
Chief Scientific Officer
Madhu Lal-Nag earned her Doctor of Philosophy (PhD) in Molecular and Cellular Oncology from George Washington University and her master’s in Bioscience Business from Keck Graduate Institute.
She aims to bridge the gap between the academic and the translational aspects of cutting-edge science in oncology, metabolic diseases, and investigative toxicology. Using the results of current therapeutic regimens to creatively translate cutting-edge research to immediately serve patient needs.Director of the Trans NIH RNAi Facility at the National Center for Advancing Translational Sciences (NCATS/NIH) and Program Director at USFDA.




Christine Schwenk
Business Development Manager
Christine Schwenk
Business Development Manager
With a BSc and MSc degree in Medical Biotechnology from Berlin, Germany, Christine began her career as a Scientist specializing in 3D in vitro cell culture and organ-on-chip systems. Transitioning into Business Development in 2020, she has since focused on driving collaborations betweem CROs and Industry for early drug discovery. Currently serving as the Business Development Manager for Nordics & UK at InSphero AG since August 2023, Christine is passionate about advancing preclinical 3D cell culture solutions and Multi-Organ-Chips for drug safety and efficacy testing. Her work is dedicated to improving the drug development processes, fostering innovation, and reducing reliance on animal testing to enhance faster development of new treatment options for patients.


Scientific Talk at Drug Discovery 2025
Unlocking Immune-Relevant Biology in Drug Discovery with InSphero’s 3D InSight™ Spheroid Platform - Biology at Scale
Date: Tuesday, October 21st, 2025 | 14:40 - 15:10
Location: Auditorium 2


Madhu Nag, PhD
Chief Scientific Officer
Madhu Nag, PhD
Chief Scientific Officer
Madhu Lal-Nag earned her Doctor of Philosophy (PhD) in Molecular and Cellular Oncology from George Washington University and her master’s in Bioscience Business from Keck Graduate Institute.
She aims to bridge the gap between the academic and the translational aspects of cutting-edge science in oncology, metabolic diseases, and investigative toxicology. Using the results of current therapeutic regimens to creatively translate cutting-edge research to immediately serve patient needs.Director of the Trans NIH RNAi Facility at the National Center for Advancing Translational Sciences (NCATS/NIH) and Program Director at USFDA.

